Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

详细信息    查看全文

• 作者：Luisa L. Villa ; Kevin A. Ault ; Anna R. Giuliano ; Ronaldo L.R. Costa ; Carlos A. Petta ; Rosires P. Andrade ; Darron R. Brown ; Alex Ferenczy ; Diane M. Harper ; Laura A. Koutsky et al.
• 关键词：Human papillomavirus ; Vaccine ; Immunogenicity
• 刊名：Vaccine
• 出版年：2006
• 出版时间：7 July 2006
• 年：2006
• 卷：24
• 期：27-28
• 页码：5571-5583
• 全文大小：442 K

文摘

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were 12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.